GBA1 and Parkinson disease: In our current study, we observed elevated levels of long-chain ceramides (Cer 23:1, Cer 24:0), predominantly in patients carrying the p.L444P mutation, which supports the idea that these lipids may contribute to the mutation-specific pathogenesis of GBA1-PD.